Table 3 Histopathological parameters and relative expression levels of galectin-1/3 mRNA in all patients with RCC
From: Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma
| Sample/pathology | n | Mean relative expression (ΔΔCt) | SD |
|---|---|---|---|
| LGALS1 | 106 | ||
| Male | 68 | 1.58 | 0.87 |
| Female | 38 | 1.37 | 0.91 |
| Age (< median) | 54 | 1.50 | 0.96 |
| Age (≥ median) | 52 | 1.48 | 0.81 |
| M0 | 83 | 1.41 | 0.90 |
| M+ | 23 | 1.77 | 0.78 |
| N0 | 95 | 1.44 | 0.86 |
| N+ | 11 | 1.97 | 1.03 |
| Localized RCC* | 57 | 1.34 | 0.89 |
| Advanced RCC* | 49 | 1.67 | 0.86 |
| Grade (≤2) | 89 | 1.46 | 0.85 |
| Grade (> 2) | 17 | 1.63 | 1.09 |
| LGALS3 | 105 | ||
| Male | 38 | -0.41 | 1.04 |
| Female | 67 | -0.06 | 0.79 |
| Age (< median) | 54 | -0.25 | 0.97 |
| Age (≥ median) | 51 | -0.12 | 0.82 |
| M0 | 82 | -0.18 | 0.90 |
| M+ | 23 | -0.23 | 0.92 |
| N0 | 94 | -0.21 | 0.86 |
| N+ | 11 | -0.001 | 1.23 |
| Localized RCC* | 56 | -0.13 | 0.91 |
| Advanced RCC* | 49 | -0.25 | 0.89 |
| Grade (≤ 2) | 88 | -1.62 | 0.9 |
| Grade (> 2) | 17 | -0.43 | 0.91 |